

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:
METALLOPROTEINASE INHIBITOR SEQUENCE RECOMBINANT VECTOR SYSTEM
FOR USING SAME AND RECOMBINANT-DNA METHOD FOR THE MANUFACTURE OF SAME
the specification of which is ☐ attached and/or ☒ was filed on October 4, 1985 as Application Serial No. 784,319 and was amended on (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NUMBER	DATE OF FILING	PRIORITY CLAIMED UNDER 35 U.S.C. §119
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION NUMBER	DATE OF FILING	STATUS (Patented, Pending, Abandoned)
699,181	2/5/85	pending

I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Finnegan, Henderson, Farabow, Garrett and Dunner, Reg. No. 22,540; Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilly, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; and
Please address all correspondence to FINNEGAN, HENDERSON, FARABOW, GARRETT AND DUNNER, 1775 K Street, N.W., Washington, D.C. 20006. Telephone No. (202) 293-6850.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Listing of Inventors Continued on Page 2 hereof ☒ Yes ☐ No

FULL NAME OF SOLE OR FIRST INVENTOR <u>David F. Carmichael</u>	INVENTOR'S SIGNATURE <i>David F. Carmichael</i>	DATE <u>22 Oct 85</u>
RESIDENCE <u>300 S. Adams Drive</u>		CITIZENSHIP <u>USA</u>
POST OFFICE ADDRESS <u>Louisville, CO 80027</u>		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY <u>David C. Anderson</u>	INVENTOR'S SIGNATURE <i>David C. Anderson</i>	DATE <u>Oct 22, 1985</u>
RESIDENCE <u>1464 Truman Ct.</u>		CITIZENSHIP <u>USA</u>
POST OFFICE ADDRESS <u>Louisville, CO 80027</u>		
FULL NAME OF THIRD JOINT INVENTOR, IF ANY <u>George P. Stricklin</u>	INVENTOR'S SIGNATURE <i>George P. Stricklin</i>	DATE <u>Oct 28, 1985</u>
RESIDENCE <u>7259 Jermyn Cove</u>		CITIZENSHIP <u>USA</u>
POST OFFICE ADDRESS <u>Germantown, TN 38119</u>		

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER • WASHINGTON, DC.

METALLOPROTEINASE INHIBITOR SEQUENCE RECOMBINANT VECTOR SYSTEM
FOR USING SAME AND RECOMBINANT-DNA METHOD FOR THE MANUFACTURE
OF SAME

FULL NAME OF FOURTH JOINT INVENTOR, IF ANY Howard G. Welgus		INVENTOR'S SIGNATURE <i>Howard G. Welgus</i>	DATE 11/1/85
RESIDENCE 109 Old Oaks Dr.		CITIZENSHIP USA	
POST OFFICE ADDRESS St. Louis, MO 63011			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF NINTH JOINT INVENTOR, IF ANY		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER • WASHINGTON, D.C.

SEQUENCE LISTING

<110> Carmichael, David F
 Anderson, David C
 Stricklin, George P
 Welgus, Howard G

<120> Human Collagenase Inhibitor, Recombinant Vector System
 For Using Same And Recombinant-DNA Method For
 Manufacture Of Same

<130> Serial No. 09/452,817

<140> 09/452,817
 <141> 1999-12-01

<150> 08/474,553
 <151> 1995-06-07

<150> 08/050,739
 <151> 1993-04-21

<150> 07/853,018
 <151> 1992-03-18

<150> 07/517,475
 <151> 1990-05-01

<150> 07/320,923
 <151> 1989-03-08

<150> 06/784,319
 <151> 1985-10-04

<150> 06/699,181
 <151> 1985-02-05

<160> 20

<170> PatentIn Ver. 2.0

<210> 1
 <211> 184
 <212> PRT
 <213> Homo sapiens

<400> 1
 Cys Thr Cys Val Pro Pro His Pro Gln Thr Ala Phe Cys Asn Ser Asp

1	5	10	15
Leu Val Ile Arg Ala Lys Phe Val Gly Thr Pro Glu Val Asn Gln Thr			
20		25	30
Thr Leu Tyr Gln Arg Tyr Glu Ile Lys Met Thr Lys Met Tyr Lys Gly			
35		40	45
Phe Gln Ala Leu Gly Asp Ala Ala Asp Ile Arg Phe Val Tyr Thr Pro			
50		55	60
Ala Met Glu Ser Val Cys Gly Tyr Phe His Arg Ser His Asn Arg Ser			
65		70	75
Glu Glu Phe Leu Ile Ala Gly Lys Leu Gln Asp Gly Leu Leu His Ile			
85		90	95
Thr Thr Cys Ser Phe Val Ala Pro Trp Asn Ser Leu Ser Leu Ala Gln			
100		105	110
Arg Arg Gly Phe Thr Lys Thr Tyr Thr Val Gly Cys Glu Glu Cys Thr			
115		120	125
Val Phe Pro Cys Leu Ser Ile Pro Cys Lys Leu Gln Ser Gly Thr His			
130		135	140
Cys Leu Trp Thr Asp Gln Leu Leu Gln Gly Ser Glu Lys Gly Phe Gln			
145		150	155
Ser Arg His Leu Ala Cys Leu Pro Arg Glu Pro Gly Leu Cys Thr Trp			
165		170	175
Gln Ser Leu Arg Ser Gln Ile Ala			
180			

<210> 2

<211> 106

<212> PRT

<213> Homo sapiens

<400> 2

Cys Thr Cys Val Pro Pro His Pro Gln Thr Ala Phe Cys Asn Ser Asp
1 5 10 15

Leu Val Ile Arg Ala Lys Phe Val Gly Thr Pro Glu Val Asn Gln Thr
20 25 30

Thr Leu Tyr Gln Arg Tyr Glu Ile Lys Met Thr Lys Met Tyr Lys Gly
35 40 45

Phe Gln Ala Leu Gly Asp Ala Ala Asp Ile Arg Phe Val Tyr Thr Pro
50 55 60

Ala Met Glu Ser Val Cys Gly Tyr Phe His Arg Ser His Asn Arg Ser
65 70 75 80

Glu Glu Phe Leu Ile Ala Gly Lys Leu Gln Asp Gly Leu Leu His Ile
85 90 95

Thr Thr Cys Ser Phe Val Ala Pro Trp Asn
100 105

<210> 3

<211> 38

<212> PRT

<213> Homo sapiens

<400> 3

Gly His Arg Arg Arg Ser Ser Ala Gln Arg Asp Thr Arg Glu Pro Thr
1 5 10 15

Met Ala Pro Phe Asp Pro Trp Leu Leu His Pro Val Val Ala Val Ala
20 25 30

Asp Ser Pro Ser Arg Ala
35

<210> 4

<211> 22

<212> PRT

<213> Homo sapiens

<400> 4

Met Ala Leu Phe Asp Pro Trp Leu Leu His Pro Val Val Ala Val Ala
1 5 10 15

Asp Ser Pro Ser Arg Ala
20

<210> 5

<211> 703

<212> DNA

<213> Homo sapiens

<400> 5

```
gttgtgtgctg tggctgatag cccacagcagg gcctgcacct gtgtcccacc ccacccacag 60
acggccttct gcaattccga cctcgtcac agggccaagt tcgtggggac accagaagtc 120
aaccagacca cttatacca gcgttatgag atcaagatga ccaagatgta taaagggttc 180
caagccttag gggatgccgc tgacatccgg ttctgtctaca ccccgccat ggagagtgtc 240
tgccgatact tccacaggtc ccacaaccgc agcgaggagt ttctcattgc tggaaaactg 300
caggatggac tcttgacat cactacctgc agttttgtgg ctccctggaa cagcctgagc 360
ttagctcagc gccggggctt caccaagacc tacactgttg gctgtgagga atgcacagt 420
tttccctgtt tatccatccc ctgcaaaactg cagagtggca ctctattgct gtggacggac 480
cagtcctctc aaggctctga aaagggttc cagtcctctc accttgctg cctgcctcgg 540
gagccagggc tgtgcacctg gcagtcctct cggtcctcaga tagcctgaat cctgcccggg 600
gtggaagctg aagcctgcac agtgtccacc ctgttccac tccatcttt ctccgggaca 660
atgaaataaa gagttaccac ccagcaaaaa aaaaaaggaa ttc 703
```

<210> 6

<211> 432

<212> DNA

<213> Homo sapiens

<400> 6

```
ggccatcgcc gcagatccag cgcccagaga gacaccagag aaccaccat ggcccccttt 60
gacctctggc ttctgcatcc tgttgttgc gtggtgata gcccagcag ggctgcacc 120
tgtgtcccac cccaccaca gacggccttc tgcaattccg acctcgcat caggccaag 180
ttcgtgggga caccagaagt caaccagacc acctataacc agcgttatga gatcaagatg 240
accaagatgt ataaagggtt ccaagcctta ggggatgccg ctgacatccg gttcgtctac 300
acccccgcca tggagagtgt ctgcggtatc ttccacaggt ccacaaccg cagcgaggag 360
tttctcattg ctggaaaact gcaggatgga ctcttgacac tcactacctg cagttttgtg 420
gctccctgga ac 432
```

<210> 7

<211> 780

<212> DNA

<213> Homo sapiens

<400> 7

```
ggccatcgcc gcagatccag cgcccagaga gacaccagag aaccaccat ggcccccttt 60
gacctctggc ttctgcatcc tgttgttgc gtggtgata gcccagcag ggctgcacc 120
tgtgtcccac cccaccaca gacggccttc tgcaattccg acctcgcat caggccaag 180
ttcgtgggga caccagaagt caaccagacc acctataacc agcgttatga gatcaagatg 240
accaagatgt ataaagggtt ccaagcctta ggggatgccg ctgacatccg gttcgtctac 300
acccccgcca tggagagtgt ctgcggtatc ttccacaggt ccacaaccg cagcgaggag 360
tttctcattg ctggaaaact gcaggatgga ctcttgacac tcactacctg cagttttgtg 420
gctccctgga acagcctgag cttagctcag gcggggggt tcaccaagac ctacactgtt 480
ggctgtgagg aatgcacagt gtttccctgt ttatccatcc cctgcaaaact gcagagtggc 540
actcattgct tgtggacgga ccagctcctc caaggctctg aaaagggtt ccagtcctct 600
caccttgctt gcctgcctcg ggagccaggg ctgtgcacct ggcagtcctt gcggtcacc 660
```

atagcctgaa tcctgcccgg agtggaagct gaagcctgca cagtgtccac cctgttccca 720
ctcccatctt tcttcggac aatgaaataa agagttacca ccagcaaaa aaaaaaagga 780

<210> 8

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
5'-end of human TIMP-1 using preferred yeats
codons; + strand

<400> 8

gatccgtgca cttgtgttcc accacaccca caaactgctt tctgtaactc tgacc 55

<210> 9

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
5'-end of human TIMP-1 using preferred yeast
codons; - strand

<400> 9

aggtcagagt tacagaaagc agtttgtggg tgtggtggaa cacaagtgca cg 52

<210> 10

<211> 75

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker

<400> 10

gatccgcgat cggagtgtaa gaaatgtgca cttgcgttcc gccgcatccg cagactgctt 60
tctgcaactc tgacc 75

<210> 11

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker

<400> 11
aggtcagagt tgcagaaagc agtctgcgga tgcggcggaa cgcaagtgca catttcttac 60
actccgatcg cg 72

<210> 12
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 12
gatccgcgat cggagtgtaa gaaatgtgca cttgc 35

<210> 13
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 13
ggaacgcaag tgcacatttc ttacactccg atcgcg 36

<210> 14
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide

<400> 14
gttcgcgcgc atccgcagac tgctttctgc aactctgacc 40

<210> 15
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:

oligonucleotide

<400> 15

aggtcagagt tgcagaaagc agtctgcgga tgcggc

36

<210> 16

<211> 9

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker

<400> 16

aattggcag

9

<210> 17

<211> 9

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker

<400> 17

tcgactgcc

9

<210> 18

<211> 138

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: artificial
OmpA leader sequence

<400> 18

gaattcgata tctcgttgga gatattcatg acgtatatttg gatgataacg aggcgcaaaa 60
aatgaaaaag acagctatcg cgatcgcagt ggcactggct ggtttcgcta ccgtagcgca 120
ggcctctggt aaaagctt 138

<210> 19

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker

<400> 19
gatcccaggc ctgca

15

```
<210> 20
<211> 7
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: linker

<400> 20
ggcctgg

7